EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSFALG00000006313
Gene Symbol: NR1H3
4 Cross references
392 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSFALG00000011082
Gene Symbol: NR1H4
4 Cross references
388 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSFALG00000008958
Gene Symbol: NR3C1
1 Cross references
280 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSFALG00000005415
Gene Symbol: NR3C2
2 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Receptor Kappa 1

Ensembl ID : ENSFALG00000010203
Gene Symbol: OPRK1
4 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Receptor Mu 1

Ensembl ID : ENSFALG00000012411
Gene Symbol: OPRM1
4 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSFALG00000010352
Gene Symbol: OPRL1
4 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Oxytocin Receptor

Ensembl ID : ENSFALG00000013622
Gene Symbol: OXTR
3 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pancreatic Alpha-Amylase-Like

Ensembl ID : ENSFALG00000002583
Gene Symbol: LOC101807262
2 Cross references
188 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSFALG00000005256
Gene Symbol: PTH1R
4 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSFALG00000002852
Gene Symbol: PPARA
4 Cross references
455 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSFALG00000003689
Gene Symbol: PPARD
4 Cross references
420 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).